Developing EZH2-Targeted Therapy for Lung Cancer

Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cance...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer discovery Vol. 6; no. 9; p. 949
Main Authors:	Frankel, Arthur E, Liu, Xin, Minna, John D
Format:	Journal Article
Language:	English
Published:	United States 01-09-2016
Subjects:	Animals Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Disease Models, Animal Drug Discovery Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors Epigenesis, Genetic - drug effects Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Lung Neoplasms - pathology Mice Molecular Targeted Therapy Xenograft Model Antitumor Assays
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2. Cancer Discov; 6(9); 949-52. ©2016 AACRSee related article by Zhang and colleagues, p. 1006.
ISSN:	2159-8290
DOI:	10.1158/2159-8290.cd-16-0800